Global Primary Immunodeficiency Therapeutics Market Size (2024 - 2029)

Primary Immunodeficiency Therapeutics Market Analysis

The Primary Immunodeficiency Therapeutics Market is expected to register a CAGR of 6.1% during the forecast period.

The COVID-19 pandemic and the lockdown restrictions imposed by the government to avoid the spread of coronavirus have impacted the market growth. According to an article published in March 2022, titled 'The Effect of COVID-19 Pandemic on Patients with Primary Immunodeficiency: A Cohort Study', the study was conducted in Iran from March 2020 to May 2021, and it has been found that among 90 primary immunodeficiency patients, 5 were having combined immunodeficiency disease and 4 were having primary antibody deficiencies (PADs). Additionally, as per a news published in January 2022, following SARS-CoV-2 infection, the United Kingdom Primary Immunodeficiency Network (UK PIN) compiled the health outcomes of 310 people with primary immunodeficiency diseases (PID) or secondary immunodeficiency diseases (SID) between March 2020 and July 2021 and it has been observed that 218 individuals were having PID and 92 SID. The COVID-19 virus poses a higher risk to people with primary and secondary immunodeficiencies because their immune systems are less capable of providing adequate defense against serious illness. Thus, impacting the market growth.

Certain factors that are propelling the market growth are the rising prevalence of immunodeficiency diseases and technological advancements in genetic therapy.

The increasing number of various immunodeficiency diseases is the key factor driving the market growth. For instance, according to an article published in January 2021, titled 'Primary immunodeficiency diseases treated with immunoglobulin and associated comorbidities', it has been observed that chronic obstructive pulmonary disease-asthma (51.5%) was statistically significantly more common as a comorbid diagnosis in the primary immunodeficiency disease population, followed by rheumatoid disease (14%), deficiency anemia (11.8%), hypothyroidism (21.2%), lymphoma (16.7%), neurologic disorders (9.7%), arrhythmias (19.9%), electrolyte disorders (23.6%), coagulopathies (16.9%), and weight loss (8.4%).

Additionally, according to an article in July 2021, titled 'Rhinitis prevalence and association with atopic dermatitis, as per the meta-analysis the pooled prevalence of rhinitis was 40.5% in patients with atopic dermatitis and 18% in patients without atopic dermatitis, in 2020. In addition, as per the same source, the pooled prevalence of rhinitis and asthma was 14.2% in patients with atopic dermatitis. Thus, the rising innate immune disorders are expected to increase the need for effective immunodeficiency therapeutics which in turn is anticipated to propel the market growth over the forecast period.

Furthermore, the rising company activities in developing products are also expected to increase the market growth over the forecast period. For instance, in October 2020, the European Commission granted orphan drug designation for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA).

However, the high cost of therapies and side effects associated with the treatment are likely to hinder the market growth over the forecast period.

Primary Immunodeficiency Therapeutics Industry Segmentation

As per the scope of the report, primary immunodeficiencies are a group of different disorders in which part of the body's immune system (mainly cells and proteins) is missing or does not function normally. The Primary Immunodeficiency Therapeutics Market is segmented By Disease Type (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, and Others), Product Type (Immunoglobulin Replacement Therapy, Stem Cell/Bone Marrow Transplantation, Antibiotic Therapy, Gene Therapy, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.